Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96 - Concepedia

Concepedia

Publication | Closed Access

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96

83

Citations

9

References

2009

Year

Keikawus Arastéh, Patrick Yéni, Anton Pozniak, Beatriz Grinsztejn, Dushyantha Jayaweera, Afsoon Roberts, Jennifer Hoy, Sandra De Meyer, Tony Vangeneugden, Frank Tomaka

Antiviral Therapy

Abstract

Treatment with DRV/r 600/100 mg twice daily was well tolerated and led to sustained virological and immunological responses in treatment-experienced HIV-1-infected patients over 96 weeks.

References

	Year	Citations

Page 1